Chemistry and Industry - Crestor takes heart
The METEOR trial examined AstraZeneca’s Crestor (rosuvastatin) in patients with early signs of atherosclerosis. C&I notes that because the METEOR study did not show regression of atherosclerosis, it ‘dashes hopes for an expanded label’ (C&I 2007, 7, 7). While METEOR did not show regression, this was not its primary endpoint. METEOR was designed to see if Crestor could halt the progression of atherosclerosis in patients at low-risk for coronary heart disease with early signs of atherosclerosis as determined by an increased carotid intima-media thickness. The study met its primary endpoint and demonstrated a slowing of progression of atherosclerosis in these patients.
Related Results
Crestor concernsWithdrawal of Crestor urgedFDA rejects Crestor petitionFurther dampener for CrestorCrestor lures consumers with coupons
Leading cardiologists, financial analysts and news outlets recognised that METEOR slowed the progression of atherosclerosis. Below please find examples of what these industry leaders have said about METEOR.
‘It met its pre-specified end point and there are not a lot of trials here at this whole meeting that met their end point.’–Steven Nissen, Reuters, 25 March, 2007
‘The core clinical message is that aggressive statin therapy seems to slow progression of atherosclerosis even in people where the LDLs are low.’–Paul Ridker, TheHeart.org, 25 March, 2007
‘The difference in growth between the Crestor and placebo groups was enough to demonstrate that Crestor significantly slowed progression.’–The Associated Press, 25 March, 2007
‘These data alongside ASTEROID demonstrate that Crestor can provide a significant disease modifying effect across the risk-spectrum of atherosclerosis.’–Deutsche Bank
‘We believe Crestor is the best statin available.’
–JP Morgan
Adam Silverstein
Edelman
COPYRIGHT 2007 Society of Chemical Industry
COPYRIGHT 2008 Gale, Cengage Learning
